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Effect of Ranitidine on 
Acetaminophen-Induced Hepatotoxicity in 
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C. PANELLA, L. MAKOWKA, M. BARONE, L. POLIMENO, S. RIZZI, J. DEMETRIS, S. BELL, 
F. W. GUGLIELMI, J. G. PRELICH, D. H. VAN THIEL, T. E. STARZL, and A. FRANCAVILLA 
The effect of ranitidine administration upon the hepatotoxic effect produced by a 
multidose acetaminophen administration regimen was examined. Seventy-two dogs 
received three subcutaneous injections of acetaminophen (750, 200, 200 mglkg body wt) in 
DMSO (600 mglml) at time zero, 9 hr later, and 24 hr after the first dose. Ten control 
animals (group I) were not given ranitidine, the remaining 62 dogs received an intramus-
cular injection of ranitidine 30 min before each acetaminophen dose. Three different doses 
ofranitidine were used (mglkg body wt): 50 mg, group II (33 dogs); 75 mg, group III (/4 
dogs); 120 mg, group IV (/5 dogs). Ranitidine reduced the expected acetaminophen-
induced hepatoxicity in a dose-response manner. Moreover, a significant correlation was 
found between the ranitidine dose and the survival rate, as evidenced by transaminase 
levels in the serum and histology of the liver. This model of fulminant hepatic failure 
induced by acetaminophen and its modulation with ranitidine provides clinical investiga-
tors with a research tool that will be useful in the future investigation of putative medical 
and surgical therapies being investigatedfor use in the clinical management offulminant 
hepatic failure. Because of the size of the animal used in this model, frequent and serial 
analyses of blood and liver were available for study to determine the effect of therapy 
within a given animal as opposed to within groups of animals. 
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Recently, a large-animal model of acute hepatic 
failure using acetaminophen was described (1). 
The two major innovations of this model include 
the use of DMSO (which does not affect transam-
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inase levels or liver and kidney histology) as the 
vehicle for the administered acetaminophen and a 
serial dosage schedule which maintains a hepato-
toxic level of acetaminophen in the animals' blood 
for several hours, thereby producing a more se-
vere and consistent hepatic necrosis with a mor-
tality rate of 90% (1). All other models of fulmi-
nant hepatic failure, particularly those using rats 
(2), rabbits (3) have been difficult to standardize, 
are not reproducible, and do not allow for serial 
observations to be made in animals that may be 
recovering. The use of large and single doses of 
ranitidine ptior to the administration of acetami-
nophen in the commonly used rat model of fulmi-
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nant hepatic failure (7) appears to reduce the 
subsequent mortality and improve the survival 
rate of the animals (8). This effect depends on the 
ability of this H2-receptor antagonist to bind cy-
tochrome P-450 (9) and inhibit microsomal hepatic 
mixed-function oxidase activity. Although cimeti-
dine is known to be the most powerful agent 
among H2-receptor antagonists with respect to its 
effect on cytochrome P-450 (10), we used raniti-
dine because it does not affect hepatic regenera-
tion, as previously shown by us and by others 
(11-13). 
In this paper, the effect of different doses of 
ranitidine on acetaminophen-induced hepatotoxic-
ity in dogs was evaluated to develop a model for 
acute hepatic failure with a predetermined mortality 
rate. 
MATERIALS AND METHODS 
Chemicals. Acetaminophen and DMSO were purchased 
from Sigma Chemical Co., St. Louis, Missouri; pentothal 
was purchased from Abbott Laboratories, North Chi-
cago, Illinois; ranitidine was obtained from Glaxo, Inc., 
Research Triangle Park, North Carolina; xylocaine was 
purchased from Astra Pharmaceutical Products, Ind., 
Worchester, Massachusetts; and formaldehyde was ob-
tained from Fisher Scientific, Pittsburgh, Pennsylvania. 
Animals. Seventy-two male beagles were purchased 
from Russel B. Hutton Farms, St. Thomas, Pennsylva-
nia. The dogs were housed in a large animal care facility, 
kept at a constant temperature of 20 ± 10 C and with a 
0600- to 1800-hr light-dark schedule. Dogs were quaran-
tined and allowed to acclimate to their surroundings for a 
minimum of one week before use. All dogs were given dry 
dog food and water ad libitum. Prior to study, their body 
weights ranged from 9-14 kg. 
Study Design. The animals were randomly divided into 
four different groups. 
Group I consisted of 10 dogs that received a total of 
three subcutaneous injections of acetaminophen in 
DMSO at a concentration of 600 mglml. The first injection 
of acetaminophen (750 mg/kg body wt) was given at noon; 
the second injection (200 mg/kg body wt) was given 9 hr 
later; the third dose (200 mglkg body wt) was given 24 hr 
after the initial dose. 
Groups II-IV consisted of 62 dogs that were adminis-
tered the acetaminophen using the same schedule as the 
dogs in group I but, in addition, were given ranitidine 
intramuscularly 30 min before each dose of acetami-
nophen at one of the following dosages: 50 mg/kg body 
wt, group II (33 dogs); 75 mglkg body wt, group III (14 
dogs); 120 mg/kg body wt, group IV (15 dogs). All animals 
were provided with intravenous glucose in amounts nec-
essary to maintain their blood sugar within normal limits 
as defined as ± 15% of the basal. 
Biochemical Determinations. In all dogs (groups I-IV), 
serum glutamic-pyruvic transaminase levels (SGPT-ALT) 
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were determined before and at scheduled times after 
acetaminophen administration using standard laboratory 
methods. Acetaminophen blood levels were determined 
in groups I and IV animals using the method described by 
Routh et al (14). 
Histology. All animals that died underwent a full 
necropsy, which included a histologic evaluation of both 
the liver and kidneys. 
Three dogs from group IV were sacrificed at 72 hr for 
histological evaluation because experience with the 
model had shown the histologic injury to be maximal at 
this time point and the probability of a long-term survival 
in an animal surviving to this point in time is greater than 
90%. 
The histology assessment of the degree of tissue necro-
sis present was performed using a semiquantitative scale. 
This scale was based on two observations: the extent of 
necrosis within individual lobules, which was classified as 
(1) mild = less than 113 of the lobule, (2) moderate 113-V3 of 
the lobule, and (3) more than V3 of the lobules being 
involved; and the number of hepatic lobules affected with 
(1) being less than 113, (2) 113-V3, and (3) greater than 7,tj of 
the lobules being affected. A score for each variable 
assessed was obtained and a mean of the two variables 
was used as the component score for the biopsy. These 
scores could range from 0-6 with no injury in any lobule 
to massive necrosis in greater than V3 of all lobules. 
Tissues were fixed in 10% neutral buffered formalin, 
sectioned at 5 ,....m and stained with hematoxylin and 
eosin. 
Statistical Analysis. The statistical analysis for the bio-
chemical determinations was performed using one-way 
analysis of variance (SPCC/PC statistical software, SPSS, 
Inc., Chicago, Illinois). The unpaired Student's t test was 
used for the analysis of the survival rates in groups I-IV. 
The relationship between long-term survival and the dose 
of ranitidine administered was examined using probit 
analysis (15). A weighted regression equation was used 
with an adjustment for natural mortality. A value of P < 
0.05 was considered to be significant. 
RESULTS 
Animal Survival. The survival rate and time 
course of the experiment for the dogs in groups 
I-IV are summarized in Figure 1. No deaths oc-
curred within the first 24 hr. A 10% mortality was 
seen in all groups except group IV within the next 
24 hr. From 48 through 72 hr, a progressive increase 
in mortality was observed in all four groups. A 
mortality of 90% at 72 hr was achieved in the 
animals in group 1. In group II, animals given 
ranitidine at a dose of 50 mg/kg body wt, a small 
(from 90% to 82%) but insignificant reduction in the 
mortality rate at 72 hr was observed. In group III, 
animals given ranitidine at a dose of 75 mg/kg body 
wt, a substantial reduction in the mortality rate 
(50%) at 72 hr was observed (P < 0.05). In group 
IV, animals given ranitidine at a dose of 120 mg/kg 
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Fig 1. Survival rate versus time in group I-IV dogs. All the 
animals received the same acetaminophen treatment. In addition 
they received a different intramuscular dose of ranitidine 30 min 
before each acetaminophen administration (mg/kg). Group I 
(control). 0 mg; group II, 50 mg; group III, 75 mg; group IV, 120 
mg. 
body wt, the mortality rate was reduced to only 
25% at 72 hr (P < 0.05). Thus, a statistically 
significant dose-response in terms of survival was 
observed with increasing doses of ranitidine from 50 
to 120 mg/kg body wt. 
Biochemical Parameters. Table 1 lists the serum 
ALT (SGPT) values in the animals at each time 
point. No difference for ALT values between 
groups of non surviving dogs was evident. Simi-
larly, no difference between groups of surviving 
animals for transaminase values was seen. How-
ever, a significant difference was observed between 
the transaminase values of surviving and nonsurviv-
ing animals across time. Surviving animals ap-
peared to have both a reduced and delayed release 
of transaminase into serum than did the nonsurviv-
ing animals. 
Figure 2 demonstrates the plasma levels of ace-
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Fig 2. Acetaminophen plasmatic levels of dogs in groups I and 
IV. Each value (mean ± SD) represents the value obtained in four 
dogs at each time. *Significantiy different from the value ob-
tained in the control animals (group I) at the same time (P < 
0.05). Inset: acetaminophen plasma levels in the animals of group 
I after initial injection. 
taminophen observed in the animals of groups I and 
IV across time. A significant difference (P < 0.05) in 
acetaminophen plasma levels after 28 hr was seen 
between the animals in groups I and IV and per-
sisted through 40 hr after the initial dosing of the 
animals. The actual acetaminophen levels present 
in the blood of dogs in group I are shown in the 
inset. 
Histopathology. The liver tissue obtained from the 
nonsurviving animals of each group demonstrated 
severe centrilobular necrosis involving 100% of the 
hepatic lobules, reticulin collapse (Figure 3A and 
B), and occasional areas of central-central bridging 
necrosis. The extent of the necrosis within individ-
ual lobules varied from a low of 40% in the least 
severely affected animals to essentially 100% necro-
TABLE 1. SERUM GLUTAMIC-PYRUVIC TRANSAMINASES (ALT-SGPT) IN NONSURVIVING AND SURVIVING DOGS FROM GROUPS I-IV AT 
DIFFERENT TIMES AFTER INTOXICATION. * 
ALT-SGPT (unitslliter) 
0.0 hr 24 hr 48 hr 72 hr 96 hr 120 hr 
Non surviving 
Group I 40 ± 14 75 ± 50 2,631,b ± 2,696 19,9S00b ± 4,200 
Group II 38 ± 17 69 ± 43 3,507'b ± 1,493 IS,601,b ± 5,426 1TIR~ ± 6,100 
Group III 29 ± 10 SI ± 46 3,001,b ± 703 12,970,b ± 4,521 
Group IV 42 ± 15 47 ± 21 3,204,b ± 1,776 12,401,b ± 3,203 13,601'b ± 2,000 
Surviving 
Group I 31 ± 14 64 ± 31 5SO" ± 278 1,706' ± 401 1,800" ± 503 1,024' ± 426 
Group II 37 ± 15 61 ± 30 711' ± 200 2,489' ± 1,900 2,907' ± 821 7,709" ± 793 
Group III 38 ± 17 65 ± 30 SIO" ± 600 3,279' ± 3,250 3,126' ± 2,613 2,017' ± 1,975 
Group IV 40 ± 15 59 ± 33 799' ± 601 2,900' ± 2,7S0 3,214' ± 2,789 7,905' ± 9,582 
*The values are expressed as mean ± SD. " P < 0.05 when the values are compared to the basal levels, b, P < 0.05 when the values 
of nonsurviving dogs are compared with the value of the surviving dogs of the same group. 
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Fig 3. Characteristic histopathologic appearance of liver in dogs from group 1. (A) Note severe centrilobular 
necrosis and hemorrhage with some preservation of periportal hepatocytes (portal tract at bottom center) (H 
& E, 200x) . (B) The damage resulted in collapse of the peri venular reticulin architecture with preservation at 
periportal areas (Re ticulin stain, 200x). PT = portal tract ; CV = central vein. 
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Fig 4. Histopathologic appearance of liver in dogs from group IV (H & E. 400 x • PT = portal tract , CV = central vein) . Note 
that there is centrilobular congestion . but cent ri lobular hepatocytes are intact and viable (arrow) . Microvesicu lar stenosis was 
also detected in hepatocytes (arrowhead). 
sis with only a thin rim of viable periportal hepato-
cytes remaining in the more severely affected ani-
mals. The hepatocellu lar necrosis in each case 
studied was associated with centrilobular conges-
tion. Individual necrotic cells demonstrated cytoag-
gregation , eosinophilia , nuclear pyknosis , karyor-
rhexsis, and karyolysis. The few residual viable 
periportal hepatocytes demonstrated cellular swell-
ing and microvacuolization. 
The histopathology of the three randomly se-
lected dogs in group IV that were sacrificed fo r 
study having a predicted 90% change of surv ival 
demonstrated a zonal necrosis involving no more 
than 700/£ of the lobules (Figure 4). In addition, the 
degree of necrosis within individual lobules varied 
from a low of 10% to a high of70%. The cells in the 
necrotic areas demonstrated cytological alterations 
similar to those described in the liver specimens 
obtained from the nonsurviving dogs . No histologic 
alterations were evident in the kidneys obtained 
from ei ther the surviving or nonsurviving dogs in 
any of the groups studied. 
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Relationship between Survival and Ranitidine Dos-
age. Figure 5 iIIustr tes the relationship between 
survival at 72 hr and thereafter and the ranitidine 
dosage used . T he curve obtained fits the following 
func tion: probit = - 2.48 + 3.94 (log lo dose). This 
function predicts the expected mortalit y at different 
dosages of ranitidine between 50 and 150 mg/kg 
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Fig S. Relations hip between final percentage of animal survival 
and the ranitidine dosage used in each group of dogs studied. 
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TABLE 2. CONFIDENCE INTERVALS FOR ESTIMATED PROBITS OF 
SURVIVAL RATE AT DIFFERENT DOSES OF RANITIDINE 
Ranitidine 
dose (mg) 
50 
75 
100 
125 
150 
Estimated 
survival % 
21.8 
46.6 
65.8 
78.6 
86.5 
95% of confidence interval 
for % survival 
12.6 .... 34.0 
36.5 .... 57.0 
51.3 .... 78.4 
60.6 .... 90.5 
67.4 .... 96.0 
body wt. Table 2 lists the survival at each dosage of 
ranitidine used using the probit analysis. Note that 
except for the higher dose of ranitidine (> 100 mg/kg 
body wt), little overlap exists between the figures. 
Moreover, despite some overlap, a group enhance-
ment of survival occurred with each incremented 
dose of ranitidine used. 
DISCUSSION 
A large animal model (1, 8) of acetaminophen-
induced hepatic failure using a protocol of multi-
dose acetaminophen administration is described. 
This model is highly reproducible and provides 
clinical investigators with a much needed large-
animal model of fulminant hepatic failure that will 
allow within-animal assessments of liver injury us-
ing serial blood sampling and liver biopsy methods 
of assessment. 
The results reported demonstrate that it is possi-
ble to ameliorate acetaminophen-induced hepato-
toxicity in this large animal model in a dose-
dependent manner with the use of ranitidine 
administered at doses ranging from 50 to 120 mg/kg 
body wt. Using a probit analysis, it is possible to 
predict the expected mortality for each dose of 
ranitidine. This should provide future investigators 
a predictable model of fulminant hepatic failure for 
any given experimental purpose that might be in-
vestigated. This model should be particularly useful 
for investigators planning to evaluate the effects of 
putative therapies for fulminant hepatic failure in 
that it provides animals with predictably different 
mortality rates for study. 
The protective effect of ranitidine observed in 
this animal model is due to its capacity to bind 
cytochrome P-450 and prevent the oxidation of 
acetaminophen to its toxic metabolites (16 .... :18). 
Ranitidine was chosen for these experiments in-
stead of cimetidine, which is a more powerful 
inhibitor of P-450 enzyme systems, in an effort to 
avoid the "hormonal" antiandrogenic influence of 
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cimetidine upon the expected hepatic regeneration 
(11-13). The data presented in Figure 2 are consis-
tent with such a hypothesis, but do not prove it. The 
amount of acetaminophen administered to the ani-
mals in group I was sufficient to induce a mortality 
rate of 90%. 
Ranitidine, particularly at very high doses, is 
known to bind to P-450 and inhibits the metabolism 
of acetaminophen. Such an effect was observed as 
ranitidine reduced both the rate of acetaminophen 
disappearance from blood (Figure 2) and the mor-
tality experienced (Figure O. 
It is of some interest that no correlation between 
the degree of hepatic injury and the dose of raniti-
dine administered to surviving animals was evident. 
The surviving animals all appeared to have a de-
layed peak in transaminase levels, probably re-
flecting a delayed production of putative acetami-
nophen toxic metabolites. The histopathologic 
studies performed in the dogs from group IV, which 
were sacrificed, clearly demonstrates the problems 
that arise in attempting to prognosticate using small 
tissue samples. Despite the low mortality rate of 
this particular group, 60 ± 20% of the hepatic 
lobules were involved in the necrotic process and 
the degree of necrosis within individual lobules 
varied widely (42 ± 20%). 
On the basis of the data presented here, the 
following four major conclusions can be drawn: (1) 
a multidose acetaminophen injection protocol used 
in conjunction with ranitidine administration is a 
reproducible method for inducing acute hepatic 
failure in dogs with a predetermined mortality rate, 
depending upon the dose of ranitidine used; (2) with 
increasing doses of ranitidine (0-120 mg/kg body 
wt), the mortality can be reduced predictably from 
90% to 25%; (3) probit analysis allows one to 
predict the expected mortality in this model for any 
dose of ranitidine used by the investigation; and (4) 
this model of acute hepatic failure should provide 
clinical investigators with a malleable tool to test 
the effect of putative therapies for fulminant hepatic 
failure. 
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